RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerMetastatic pancreatic cancer is a rare and orphan disease state that is proving to be the best route for pelareorep to achieve approval based on the Accelerated Approval proces involving ONCY's CelTils biomarker work that the Aware-1 study identified as surrogate endpoints.